About this Video
Biology dogma: DNA — mRNA — proteins. The biotech industry has made wonders for patients in the last 30 years making recombinant proteins, like EPO and insulin. What if mRNA could be a drug and the body could make its own missing proteins on demand?
Stephane Bancel is the founding CEO of moderna Therapeutics in Cambridge, MA.
About the Speaker
Stéphane has served as Moderna’s chief executive officer since October 2011 and as a member of Moderna’s board of directors since March 2011. Before joining the company, Mr. Bancel served for five years as chief executive officer of the French diagnostics company bioMérieux SA. From July 2000 to March 2006, he served in various roles at Eli Lilly and Company, including as managing director for Belgium and as executive director of global manufacturing strategy and supply chain. Prior to his work at Lilly, Stéphane served as Asia-Pacific sales and marketing director for bioMérieux. Stéphane currently serves on the board of directors of Generate Biomedicines and Qiagen N.V., and he previously served on the boards of BG Medicine, Inc. and Syros Pharmaceuticals, Inc. (Nasdaq: SYRS). He is a venture partner at Flagship Pioneering and a trustee of the Museum of Science in Boston. Stéphane holds a master of engineering degree from École Centrale Paris (ECP), a master’s of science in chemical engineering from the University of Minnesota, and an MBA from Harvard Business School.